ADA-07
ADA-07 is a TOPK inhibitor with activity at the ATP-binding pocket that does not inhibit MEK1 activity. ADA-07 suppresses solar ultraviolet (SUV)-induced phosphorylation of ERK1/2, p38, and JNKs, and inhibits AP-1 activity. ADA-07 attenuates tumor incidence, multiplicity, and volume in SUV-exposed SKH-1 hairless mice. ADA-07 can be used for the research of solar ultraviolet-induced skin carcinogenesis.
For research use only. We do not sell to patients.
- CAS No.: 2252153-94-7
- Formula: C18H20N2O2
- Molecular Weight:296.37
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All AP-1 Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
TOPK |
ERK1 |
ERK2 |
p38 |
JNK |
AP-1 |
In Vitro
ADA-07 binds directly to the ATP-binding pocket of TOPK via hydrogen bonding with Gly118 and Gly119[1].
ADA-07 binds TOPK in an ATP-competitive manner[1].
ADA-07 (2.5 mg; overnight) binds to endogenous TOPK and MEK1/2 present in HaCaT human skin keratinocyte lysates[1].
ADA-07 (0.5-5 μM; 30 min) potently and selectively inhibits the kinase activity of active human recombinant TOPK, but does not inhibit active human recombinant MEK1[1].
ADA-07 (1.25-10 μM; 24-48 h) is non-cytotoxic to JB6 P+ mouse epidermal cells and NHDF normal human dermal fibroblasts at concentrations below 10 μM after 24 or 48 h of incubation[1].
ADA-07 (1.25-5 μM; 4 h pre-incubation) dose-dependently inhibits SUV-induced phosphorylation of ERK1/2, p38, JNKs, and c-Jun in HaCaT human skin keratinocytes and JB6 P+ mouse epidermal cells[1].
ADA-07 (1.25-5 μM; 24 h) dose-dependently inhibits basal phosphorylation of ERK1/2, p38, JNKs, and c-Jun in SCC12 human squamous cell carcinoma cells and A431 human epidermoid carcinoma cells[1].
ADA-07 (1.25-5 μM; 1 h pre-incubation) dose-dependently inhibits SUV-induced AP-1 transactivation in JB6 P+ mouse epidermal cells stably expressing an AP-1 luciferase reporter[1].
ADA-07 (1.25-10 μM; 1-2 weeks) dose-dependently inhibits EGF-induced neoplastic transformation of JB6 P+ mouse epidermal cells in an anchorage-independent growth assay[1].
ADA-07 (0.625-10 μM; several days) dose-dependently suppresses the proliferation of SCC12 human squamous cell carcinoma cells and A431 human epidermoid carcinoma cells in a crystal violet staining assay[1].
ADA-07 (1.25-5 μM; 24 h) suppresses AP-1 activity in control A431 human epidermoid carcinoma cells in a dose-dependent manner, but has minimal effect on AP-1 activity in TOPK-knockdown A431 cells, confirming that ADA-07 acts by targeting TOPK[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:JB6 P+ mouse epidermal cells, NHDF normal human dermal fibroblasts
-
Concentration:1.25 μM; 2.5 μM; 5 μM; 10 μM
-
Incubation Time:24 h; 48 h
-
Result:Showed no cytotoxicity at concentrations less than 10 μM in both JB6 P+ mouse epidermal cells and NHDF normal human dermal fibroblasts.
-
Cell Line:SCC12 human squamous cell carcinoma cells, A431 human epidermoid carcinoma cells
-
Concentration:0.625 μM; 1.25 μM; 2.5 μM; 5 μM; 10 μM
-
Incubation Time:several days
-
Result:Decreased cell proliferation strongly in both SCC12 and A431 cells in a dose-dependent manner, with significant inhibition observed starting at 1.25 μM.
-
Cell Line:HaCaT human skin keratinocytes, JB6 P+ mouse epidermal cells
-
Concentration:1.25 μM; 2.5 μM; 5 μM ; 60 kJ UVA/m2, 2.9 kJ UVB/m2 SUV
-
Incubation Time:4 h (ADA-07 pre-incubation); 15 min (post-SUV exposure incubation)
-
Result:Suppressed SUV-induced phosphorylation of ERK1/2, p38, and JNKs in a dose-dependent manner in both HaCaT and JB6 P+ cells.
Suppressed SUV-induced phosphorylation of c-Jun in a dose-dependent manner in both cell lines.
Showed no significant changes in phosphorylated or total TOPK protein levels.
-
Cell Line:SCC12 human squamous cell carcinoma cells, A431 human epidermoid carcinoma cells
-
Concentration:1.25 μM; 2.5 μM; 5 μM
-
Incubation Time:24 h
-
Result:Blocked phosphorylation of ERK1/2, p38, and JNKs in a dose-dependent manner in both SCC12 and A431 cells.
Attenuated phosphorylation of c-Jun in a dose-dependent manner in both cell lines.
Showed no significant changes in phosphorylated or total TOPK protein levels.
In Vivo
ADA-07 (0.1-1 mg; topical; 3 times weekly; 13 weeks) significantly suppresses established SUV-induced skin carcinogenesis in SKH-1 hairless mice by inhibiting SUV-induced phosphorylation of ERK1/2, p38, and JNKs and reducing cell proliferation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:SKH-1 hairless mice (female, 6-8 weeks old, mean body weight 25 g, chronic solar ultraviolet-induced skin carcinogenesis early-stage prevention model)[1]
-
Dosage:0.1 mg; 1 mg
-
Administration:topical; 3 times weekly; 28 weeks
-
Result:Completely inhibited SUV-induced papilloma formation.
Reduced SUV-induced epidermal thickness.
Decreased PCNA expression (a marker of cell proliferation).
Suppressed SUV-induced phosphorylation of ERK1/2, p38, and JNKs in mouse skin.
-
Animal Model:SKH-1 hairless mice (female, 6-8 weeks old, mean body weight 25 g, chronic solar ultraviolet-induced skin carcinogenesis late-stage prevention model)[1]
-
Dosage:0.1 mg; 1 mg
-
Administration:topical; 3 times weekly; 13 weeks
-
Result:Substantially suppressed SUV-induced tumor incidence.
Significantly reduced tumor volume and multiplicity.
Decreased SUV-induced epidermal thickness.
Inhibited SCC formation.
Decreased PCNA expression.
Suppressed SUV-induced phosphorylation of ERK1/2, p38, and JNKs in mouse skin.
Chemical Information
-
CAS No. 2252153-94-7
-
Molecular Weight 296.37
-
Formula C18H20N2O2
-
SMILES
O=C1NC2=CC=C(C=C2C1=NO)C34CC5CC(CC(C5)C3)C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)